The General Hospital Corporation

David Tomoaki Miyamoto

Daniel Arie Haber

Shyamala Maheswaran

Tanya Todorova

Xin Hong

Mark Kalinich

Mehmet Toner

Ravi Kapur

Sarah Javaid

Tanya Todorova Kwan

This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.

Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.

Digital analysis of circulating tumor cells in blood samples

Provided herein are assays and methods related to determining a ratio of expression levels of PSA/PSMA or determining the expression level of PSMA in circulating tumor cells for diagnosis and/or for the purpose of monitoring treatment efficacy for prostate cancers that are likely hormone resistant.

Diagnosis and monitoring treatment of prostate cancer

Growing community of inventors

Wellesley, MA, United States of America

David Tomoaki Miyamoto